Other Cancer Types

Aspirin's evidence base extends beyond the main cancer-type pages.

Some signals are real but still too limited, mixed, or subtype-specific to justify a full standalone page.

This page holds those shorter summaries in one place.

How to read this page

These are short evidence summaries, not full cancer pages yet.

That usually means one of three things:

• the signal is real but still mixed

• the evidence is only strong in a narrow subtype

• the biology is interesting, but the human data is still thin

Bladder cancer

Bladder cancer needs careful handling because the signal is genuinely mixed.

Some post-diagnosis studies suggest a survival benefit with aspirin use after diagnosis, including in people taking aspirin three or more times per week. That makes bladder cancer a possible supportive-survival discussion rather than an easy prevention page.

But the prevention story is not clean. Some longer-term population cohorts in otherwise healthy people have reported higher bladder-cancer incidence in aspirin users.

That does not prove aspirin causes bladder cancer. It does mean the signal is too conflicted to frame as a straightforward positive page.

Practical position

• Post-diagnosis use: Possible supportive survival signal

• Prevention before diagnosis: Mixed and potentially misleading if oversimplified

• Current status: Keep here as a balanced caution-and-signal summary

Lymphoma

Lymphoma is not one disease.

That matters more than usual here. The aspirin signal appears subtype-specific, with the strongest supportive associations reported in diffuse large B-cell lymphoma, or DLBCL.

Some haematologic malignancies show a protective association with aspirin exposure. But the effect is not broad enough across all lymphomas to justify a single positive lymphoma page without more qualification.

Practical position

• Best-supported area: DLBCL

• Main limit: Evidence does not generalise cleanly across all lymphoma subtypes

• Current status: Worth keeping as a short summary, with room for later subtype expansion

Cervical cancer

Cervical cancer has a plausible aspirin biology, but the direct evidence is still limited.

The strongest rationale is molecular. PIK3CA mutations occur in roughly 20% to 30% of cervical cancers, which creates a biologically interesting overlap with aspirin-sensitive pathway logic seen more clearly in colorectal cancer.

The problem is that the epidemiological evidence is still limited and inconsistent. That keeps cervical cancer in the “interesting but not established” category.

Practical position

• Biological rationale: Real, especially in PIK3CA-mutant disease

• Human evidence: Limited and inconsistent

• Current status: Appropriate as a brief placeholder summary, not a full page yet

Not included yet

Some cancer types should stay out of the positive evidence list for now.

Leukaemia

This should be handled as a caution, not a candidate aspirin page.

Two major cohorts now report aspirin association with higher leukaemia risk. That is exactly the kind of signal that should be noted carefully rather than folded into a positive evidence section.

Head and neck cancer

This also stays out for now.

At least one cohort has reported higher risk with long-term aspirin use. The wider evidence remains inconsistent, and there is not enough support for a positive summary page.

Renal cell carcinoma

This does not currently justify a page.

An older small randomised trial with 176 patients did not show a significant survival benefit, and the modern evidence base remains limited.

Small bowel cancer

There is some signal in neuroendocrine tumours, but it is too narrow and too early for a standalone page in this aspirin section.

Practical interpretation

This page is where aspirin signals go when they are:

• too mixed for a confident positive page

• too narrow to generalise beyond a subtype

• biologically interesting, but not ready for full expansion

The most important message here is restraint.

Not every mechanistic hint deserves a full disease page. And not every observational signal should be read as supportive.

References

General aspirin and cancer reviews
https://pmc.ncbi.nlm.nih.gov/

Repurposing reviews
https://www.dovepress.com/

Aspirin and metastasis / platelet biology context
https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form